Liquidia Corporation Intrinsic Value Calculator – LIQUIDIA CORPORATION Reports 22.2% Increase in Total Revenue for Q2 of FY2023
August 12, 2023
☀️Earnings Overview
On June 30, 2023, LIQUIDIA CORPORATION ($NASDAQ:LQDA) reported its second quarter earnings for FY2023, showing total revenue of USD 4.8 million, a 22.2% increase year-over-year. Meanwhile, net income for the quarter decreased by -9.4 million from the same period last year, reaching USD -23.5 million.
Analysis – Liquidia Corporation Intrinsic Value Calculator
GoodWhale recently conducted an in-depth analysis of LIQUIDIA CORPORATION‘s wellbeing. Using our proprietary Valuation Line, we were able to calculate the intrinsic value of LIQUIDIA CORPORATION’s shares at around $6.4. Surprisingly, the current trading price of LIQUIDIA CORPORATION’s shares is at $7.9, which is overvalued by 22.5%. This means investors should be cautious when investing in LIQUIDIA CORPORATION, as they could be taking on excessively high risk for a potentially low return. More…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Liquidia Corporation. More…
| Total Revenues | Net Income | Net Margin |
| 17.8 | -50.89 | -272.8% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Liquidia Corporation. More…
| Operations | Investing | Financing |
| -24.4 | -1.19 | 9.95 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Liquidia Corporation. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 121.6 | 60.94 | 0.94 |
Key Ratios Snapshot
Some of the financial key ratios for Liquidia Corporation are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 25.4% | – | -264.1% |
| FCF Margin | ROE | ROA |
| -143.7% | -41.3% | -24.2% |
Peers
The competition between Liquidia Corp and its competitors is fierce. Each company is vying for a share of the market, and each is eager to prove its superiority. Liquidia Corp is a leading player in the industry, and its competitors are well aware of this. They are all striving to beat Liquidia Corp at its own game, and they are all determined to win.
– Fusion Antibodies PLC ($LSE:FAB)
Fusion Antibodies PLC is a clinical-stage biopharmaceutical company focused on the development of novel antibody-based therapies for the treatment of cancer. The company’s lead product candidate is FT-7051, an antibody-drug conjugate (ADC) that is being evaluated in a phase 1/2 clinical trial in patients with advanced solid tumors. Fusion Antibodies PLC has a market cap of 10.02M as of 2022 and a Return on Equity of -20.87%.
– SinoMab BioScience Ltd ($SEHK:03681)
SinoMab BioScience Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibody therapeutics for the treatment of cancer and other unmet medical needs. The company’s lead product candidate is MMJ-001, a monoclonal antibody that targets the protein ROR1, which is overexpressed in various solid tumors and hematologic malignancies. SinoMab BioScience is headquartered in Beijing, China.
SinoMab BioScience Ltd has a market cap of 1.81B as of December 2020. The company’s ROE for the same period was -31.24%. The company’s lead product candidate is MMJ-001, a monoclonal antibody that targets the protein ROR1, which is overexpressed in various solid tumors and hematologic malignancies.
– TRACON Pharmaceuticals Inc ($NASDAQ:TCON)
TRACON Pharmaceuticals Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for cancer and other underserved medical needs. The Company’s product candidates include TRC105, TRC196 and TRC253. TRC105 is an endoglin antibody in Phase II clinical trials for the treatment of solid tumors. TRC196 is an antibody that inhibits angiopoietin-2 in Phase I/II clinical trials for the treatment of solid tumors. TRC253 is a small molecule kinase inhibitor in Phase I/II clinical trials for the treatment of solid tumors.
Summary
LIQUIDIA CORPORATION reported second quarter earnings results for FY2023, with total revenue of USD 4.8 million, a 22.2% increase from the same period the previous year. Net income for the second quarter was USD -23.5 million, down -9.4 million from the same period in the prior year. The stock price responded positively to these results, moving up on the same day.
This suggests that investors remain confident in LIQUIDIA CORPORATION’s prospects and that their business fundamentals remain strong. With the company’s second quarter earnings showing strong revenue growth, it appears that LIQUIDIA CORPORATION is well-positioned to meet their long-term goals and investors may be wise to consider investing in this company.
Related Posts
Recent Posts
